Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2019

Transgene Announces Financial Calendar for 2020

20191218 Financial calendar 2020 EN

Published 18 December 2019
Categorized as 2019, Press release

Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer

20191212 PR TG4010_EN_results

Published 12 December 2019
Categorized as 2019, Press release, TG4010

Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors

20191211 PR preclinical BT001 EN

Published 11 December 2019
Categorized as 2019, BT-001, Invir.IO, Press release

Transgene Announces Investor Meetings for January 2020

20191209 PR Investors Meeting agenda 2020

Published 9 December 2019
Categorized as 2019, Press release

Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001

20191114 Résultats T3-2019 EN

Published 14 November 2019
Categorized as 2019, Press release

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_MetaanalyseFabien Zoulim et al.AASLD 2019Download the poster herePoster Presentation

Published 8 November 2019
Categorized as -others, 2019, Publication, TG1050

Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming

Transgene SITC 2019 PosterJean-Baptiste Marchand et al.SITC 2019Download the poster herePoster Presentation

Published 6 November 2019
Categorized as -others, 2019, Invir.IO, Publication

Transgene Will Participate in the Jefferies 2019 London Healthcare Conference

20191022 – Transgene PR Jefferies EN

Published 22 October 2019
Categorized as 2019, Press release

Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers

Christophe Le Tourneau et al. ESMO 2019 Download the poster here Poster Presentation

Published 30 September 2019
Categorized as -others, 2018, 2019, Publication, TG4001, TG4001, TG6002 (FR)

Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019

20190930 PR TG4001 ESMO EN

Published 30 September 2019
Categorized as 2019, Press release, TG4001, TG4001

Posts pagination

Page 1 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu